Clinical Scorecard: FDA approves asundexian to reduce recurrent stroke risk
At a Glance
| Category | Detail |
|---|---|
| Condition | Reducing stroke risk after a recent noncardioembolic ischemic stroke or high-risk transient ischemic attack (TIA) |
| Key Mechanisms | Asundexian inhibits activated factor XI, reducing amplification of thrombin generation and thrombus formation through the intrinsic coagulation pathway. |
| Target Population | Adults with a recent noncardioembolic ischemic stroke and NIH Stroke Scale score of 15 or lower, or a high-risk TIA; the indication does not include stroke prevention in patients with atrial fibrillation. |
| Care Setting | After recent ischemic stroke or high-risk TIA, with asundexian used alongside antiplatelet therapy. |
Key Highlights
- FDA approved asundexian 50 mg orally once daily in combination with antiplatelet therapy.
- In OCEANIC-STROKE, ischemic stroke occurred in 6.2% of asundexian recipients and 8.4% of placebo recipients, representing a 26% relative risk reduction.
- Major bleeding rates were similar overall: 1.6 versus 1.5 events per 100 person-years.
- Major bleeding rates were higher with asundexian among patients older than 75 years and during the first 90 days of treatment; gastrointestinal bleeding was also more frequent.
- The FDA prescribing information does not recommend routine coagulation monitoring and lists no contraindications.
Guideline-Based Recommendations
Diagnosis
- The FDA-approved population includes adults with a recent noncardioembolic ischemic stroke and NIH Stroke Scale score of 15 or lower, or a high-risk TIA.
- The indication does not extend to stroke prevention in patients with atrial fibrillation.
Management
- The FDA prescribing information specifies asundexian 50 mg once daily in combination with antiplatelet therapy.
- Withhold treatment for at least 24 hours before elective procedures and resume once adequate hemostasis is established.
- Withhold treatment for at least 24 hours after thrombolysis for acute ischemic stroke.
- Avoid concomitant use with combined P-glycoprotein and strong CYP3A4 inducers, including carbamazepine.
- Use is not recommended in patients with moderate or severe hepatic impairment.
Monitoring & Follow-up
- The FDA prescribing information does not recommend routine coagulation monitoring.
- Hepatic enzyme elevations were reported more frequently with asundexian.
Risks
- Major bleeding was higher with asundexian among patients older than 75 years (2.6 vs 1.7 events per 100 person-years) and during the first 90 days (4.5 vs 3.1 events per 100 person-years).
- Gastrointestinal bleeding occurred at 2.7 versus 2.1 events per 100 person-years.
- Diarrhea occurred in 3.4% of asundexian recipients versus 2.8% of placebo recipients.
- Concomitant combined P-glycoprotein and strong CYP3A4 inducers may reduce efficacy.
Patient & Prescribing Data
Adults with a recent noncardioembolic ischemic stroke (NIH Stroke Scale score 15 or lower) or high-risk TIA; not indicated for stroke prevention in atrial fibrillation.
The approved dose is 50 mg orally once daily with antiplatelet therapy. In OCEANIC-STROKE, participants were assigned within 72 hours of symptom onset, and median treatment duration was 14.2 months.
Clinical Best Practices
- The FDA prescribing information specifies use within the approved population and in combination with antiplatelet therapy.
- Follow the FDA prescribing information for withholding treatment before elective procedures and after thrombolysis.
- Follow the FDA prescribing information regarding interacting inducers and use in moderate or severe hepatic impairment.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
